What is GLP1 that is the key to the new weight loss drug Ozempic and how Yerba Mate Tea could have similar effects and help with fasting (2023)

by IF Tea Company

By now you may have seen the articles covering the new wonder diabetes drug Ozempic and how its having real positive results for weight loss. This article is going to explore briefly how it works and how Yerba Mate can have similar effects and be a beneficial tea for anyone fasting or wanting to lose weight.

UPDATE: Since posting our article, new information has come out on Ozempic, it is still a very beneficial drug for weight loss but there are potential side effects. You can read more about the full benefits and side effects of it at DrugWatch.com at the following links
https://www.drugwatch.com/drugs/ozempic/



If you're looking for a great tea, take a look at our IF Tea - it combines Yerba Mate, Green Tea and Black Tea as well as several other beneficial ingredients to help with appetite and metabolism. 

Participants who received semaglutide lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group.

SCROLL TO THE BOTTOM TO SEE RESEARCH / STUDIES THAT SHOW POSITIVE RESULTS OF OZEMPIC

Ozempic® acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1

The hormone GLP-1, also known as glucagon-like peptide-1, is made in the stomach and is essential for controlling blood sugar levels and appetite. In reaction to food intake, specialized cells in the intestine release GLP-1 when we eat.

GLP-1 acts by encouraging the pancreas to release more insulin, which lowers blood sugar levels. Additionally, it slows down the rate at which food passes through the stomach and bowels, which may assist in lowering hunger levels and enhancing feelings of fullness.

Additionally, it has been shown that GLP-1 can block the creation of ghrelin, a hormone that increases hunger. GLP-1 may aid in decreasing cravings and promoting feelings of fullness by lowering ghrelin production.

GLP-1 has also been proven to possibly enhance pancreatic and liver function, which may benefit blood sugar regulation and metabolism.

The development of new drugs for the treatment of obesity and type 2 diabetes has turned GLP-1 into a target due to its effects on appetite control and blood sugar regulation.

How Yerba Mate could produce similar effects?

Yerba mate may stimulate the body's production of GLP-1, in accordance with some research. In a study done in 2017 that appeared in the journal Nutrition & Diabetes, it was discovered that overweight and obese people who drank yerba mate every day for 12 weeks had higher GLP-1 levels than people who didn't.

Another study showed that yerba mate consumption raised GLP-1 levels in healthy people, which was reported in the journal Nutrition Research in 2015.

While these studies indicate that yerba mate might increase the body's production of GLP-1, more investigation is required to completely comprehend the mechanisms underlying this effect.

If you're interested in utilizing Tea to help with appetite, fasting or metabolism, we welcome you to look at our Fasting Tea and see if it could help!

 

OZEMPIC = SEMAGLUTIDE

  1. In a 68-week study published in the New England Journal of Medicine in 2021, researchers found that semaglutide led to significant weight loss in overweight or obese adults with or without type 2 diabetes. Participants who received semaglutide lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group.

  2. Another study published in The Lancet Diabetes & Endocrinology in 2021 compared the effects of semaglutide to a placebo in overweight or obese adults with type 2 diabetes. Participants who received semaglutide lost an average of 9.6% of their body weight, compared to 3.4% in the placebo group.

  3. A systematic review and meta-analysis published in Obesity Reviews in 2021 analyzed the results of 11 randomized controlled trials of semaglutide for weight loss. The study found that semaglutide led to significant weight loss compared to placebo, with an average weight loss of 9.5 kg (20.9 lbs) after 52 weeks of treatment.

  4. A study published in Diabetes Care in 2019 looked at the effects of semaglutide on weight loss and cardiovascular risk factors in patients with type 2 diabetes. Participants who received semaglutide lost an average of 6.0% of their body weight, compared to 1.4% in the placebo group. The study also found that semaglutide improved several cardiovascular risk factors, including blood pressure and cholesterol levels.

Back to News